QIAGEN N.V. (QGEN)

Market Closed

3 Jun, 20:00

NYSE

36. 45

+0.76

+2.13%

7.55B Market Cap

26.32 P/E Ratio

1.28% Div Yield

2,980,378 Volume

2.11 Eps

$ 35.69

Previous Close

Investors:

NRG

+25

Add Transaction

Day Range

35.47 36.5

Year Range

32.53 57.82

Want to track QGEN and more in your Portfolio? 🎯

Get Started For Free

Why Is Qiagen (QGEN) Down 9.4% Since Last Earnings Report?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Zacks | 2 months ago

Qiagen N.V. (QGEN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seekingalpha | 3 months ago

QGEN's Q4 Earnings Meet Estimates, Revenues Up Y/Y, Stock Down

QIAGEN shares decline as Q4 earnings meet estimates and revenues beat, with margin contraction and cautious 2026 guidance in focus.

Zacks | 3 months ago

Qiagen N.V. (QGEN) Q4 2025 Earnings Call Transcript

Seekingalpha | 3 months ago

Qiagen (QGEN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 3 months ago

Qiagen (QGEN) Meets Q4 Earnings Estimates

Qiagen (QGEN) came out with quarterly earnings of $0.62 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.64 per share a year ago.

Zacks | 3 months ago

Earnings Preview: Qiagen (QGEN) Q4 Earnings Expected to Decline

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 4 months ago

Qiagen: Takeover Optionality With A High-Quality Consumables Platform

QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there's renewed takeover speculation after reports that show they're weighing strategic options. QGEN's potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed.

Seekingalpha | 4 months ago